

**Scemblemx(asciminib)
Prior Authorization Request Form**

Caterpillar Prescription Drug Benefit
Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: _____ **MEMBER'S FIRST NAME:** _____

Instructions: Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

URGENT

MEMBER INFORMATION		
LAST NAME:	FIRST NAME:	
PHONE NUMBER:	DATE OF BIRTH:	
STREET ADDRESS:		
CITY:	STATE:	ZIP CODE:
PATIENT INSURANCE ID NUMBER:		

MALE FEMALE HEIGHT (IN/CM): _____ WEIGHT (LB/KG): _____ ALLERGIES: _____

IF YOU ARE NOT THE PATIENT OR THE PRESCRIBER, YOU WILL NEED TO SUBMIT A PHI DISCLOSURE AUTHORIZATION FORM WITH THIS REQUEST WHICH CAN BE FOUND AT THE FOLLOWING LINK: [PRIMETHERAPEUTICS.COM/NOPP](https://www.primetherapeutics.com/nopp)

PATIENT'S AUTHORIZED REPRESENTATIVE (IF APPLICABLE): _____
AUTHORIZED REPRESENTATIVE'S PHONE NUMBER: _____

PRESCRIBER INFORMATION			
LAST NAME:	FIRST NAME:		
PRESCRIBER SPECIALTY:	EMAIL ADDRESS:		
NPI NUMBER:	DEA NUMBER:		
PHONE NUMBER:	FAX NUMBER:		
STREET ADDRESS:			
CITY:	STATE:	ZIP CODE:	
REQUESTER (if different than prescriber):	OFFICE CONTACT PERSON:		

MEDICATION OR MEDICAL DISPENSING INFORMATION			
MEDICATION NAME:			
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFILLS:	QUANTITY:
<input type="checkbox"/> NEW THERAPY <input type="checkbox"/> RENEWAL IF RENEWAL: DATE THERAPY INITIATED:			
DURATION OF THERAPY (SPECIFIC DATES):			

Continued on next page

Scemblemx(asciminib)
Prior Authorization Request Form
 Caterpillar Prescription Drug Benefit
 Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: _____ MEMBER'S FIRST NAME: _____

1. HAS THE PATIENT TRIED ANY OTHER MEDICATIONS FOR THIS CONDITION?		
<input type="checkbox"/> YES (if yes, complete below) <input type="checkbox"/> NO		
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE):	DURATION OF THERAPY (SPECIFY DATES):	RESPONSE/REASON FOR FAILURE/ALLERGY:
2. LIST DIAGNOSES:		ICD-10:
<input type="checkbox"/> Chronic Myeloid Leukemia (CML) <input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s):		
3. REQUIRED CLINICAL INFORMATION: PLEASE PROVIDE ALL RELEVANT CLINICAL INFORMATION TO SUPPORT A PRIOR AUTHORIZATION.		
Is patient going to be using drug in combination with a clinical trial? <input type="checkbox"/> Yes <input type="checkbox"/> No		
Is the patient's disease Philadelphia chromosome-positive (Ph+)? <input type="checkbox"/> Yes <input type="checkbox"/> No <i>Please provide documentation.</i>		
Does the patient have chronic phase disease? <input type="checkbox"/> Yes <input type="checkbox"/> No <i>Please provide chart note documentation.</i>		
Is the patient resistant, or intolerant, or had an inadequate response to prior therapy consisting of a 3 month trial or longer, with at least 2 tyrosine kinase inhibitor (e.g., imatinib, dasatinib, ponatinib, nilotinib, etc.)? <input type="checkbox"/> Yes <input type="checkbox"/> No <i>(provide documentation of dates and drugs)</i>		
Does the patient have the T3151 mutation? <input type="checkbox"/> Yes <input type="checkbox"/> No <i>Please provide documentation.</i>		
Has the patient trialed and failed Iclusig (ponatinib)? <input type="checkbox"/> Yes <input type="checkbox"/> No <i>(provide documentation dates)</i>		
Is the patient newly diagnosed(within 3 months of diagnosis) Philadelphia chromosome-positive chronic myeloid leukemia(Ph+CML) ? <input type="checkbox"/> Yes <input type="checkbox"/> No <i>Please provide documentation.</i>		
Does patient have < 15% blasts in peripheral blood and bone marrow? <input type="checkbox"/> Yes <input type="checkbox"/> No <i>Please provide documentation.</i>		
Does patient have < 30% blasts plus promyelocytes in peripheral blood and bone marrow? <input type="checkbox"/> Yes <input type="checkbox"/> No <i>Please provide documentation.</i>		
Does patient have < 20% basophils in the peripheral blood? <input type="checkbox"/> Yes <input type="checkbox"/> No <i>Please provide documentation.</i>		
Does patient have a platelet count $\geq 100 \times 10^9/L$ ($\geq 100,000/mm^3$)? <input type="checkbox"/> Yes <input type="checkbox"/> No <i>Please provide documentation.</i>		

**Scemblemx(asciminib)
Prior Authorization Request Form**

Caterpillar Prescription Drug Benefit
Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: _____ **MEMBER'S FIRST NAME:** _____

Does patient have evidence of extramedullary leukemic involvement(with the exception of hepatosplenomegaly)? Yes No *Please provide documentation.*

Does patient have an Eastern Cooperative Oncology Group (ECOG) performance status of 0,or 1. 5? Yes No

Has patient been previously treated for their newly diagnosed Ph+ CML, including chemotherapy and/or biologic agents or prior stem cell transplant, with the exception of hydroxyurea and/or anagrelide? Yes No *Please provide documentation.*

Does patient have known cytopathologically confirmed CNS infiltration? Yes No *Please provide documentation.*

For Renewal, answer the following:

Does the patient continue to demonstrate a positive clinical response? Yes No *Please provide documentation*

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: Not all drugs/diagnosis are covered on all plans. This request may be denied unless all required information is received.

ATTESTATION: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

Prescriber Signature or Electronic I.D. Verification: _____ **Date:** _____

CONFIDENTIALITY NOTICE: The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return FAX) and arrange for the return or destruction of these documents.

FAX THIS FORM TO: 800-424-7640

MAIL REQUESTS TO: Prime Therapeutics Management Prior Authorization Program

Attn: CP-4201

P.O. Box 64811

St. Paul, MN 55164-0811

Phone: 877-228-7909